RB0 Stock Overview A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
REGENXBIO Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for REGENXBIO Historical stock prices Current Share Price US$7.60 52 Week High US$23.60 52 Week Low US$6.75 Beta 1.28 1 Month Change 0.66% 3 Month Change -3.80% 1 Year Change -34.48% 3 Year Change -64.63% 5 Year Change -83.17% Change since IPO -64.83%
Recent News & Updates Abbvie and Regenxbio Inc. Announce Updates on the Abbv-Rgx-314 Clinical Program Jan 13
REGENXBIO Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Dec 10
Regenxbio Initiates Pivotal Phase of Affinity Duchenne Trial of RGX-202 Gene Therapy and Reports Positive Functional Data Nov 19
Third quarter 2024 earnings released: US$1.17 loss per share (vs US$1.41 loss in 3Q 2023) Nov 08 REGENXBIO Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 30
REGENXBIO Inc. Announces Chief Financial Officer Changes Sep 18 See more updates Abbvie and Regenxbio Inc. Announce Updates on the Abbv-Rgx-314 Clinical Program Jan 13
REGENXBIO Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Dec 10
Regenxbio Initiates Pivotal Phase of Affinity Duchenne Trial of RGX-202 Gene Therapy and Reports Positive Functional Data Nov 19
Third quarter 2024 earnings released: US$1.17 loss per share (vs US$1.41 loss in 3Q 2023) Nov 08 REGENXBIO Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 30
REGENXBIO Inc. Announces Chief Financial Officer Changes Sep 18 REGENXBIO Inc. Announces Executive Changes
REGENXBIO Inc. Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect Sep 04
Second quarter 2024 earnings released: US$1.05 loss per share (vs US$1.66 loss in 2Q 2023) Aug 02
REGENXBIO Inc. Reports New, Positive Interim Safety and Efficacy Data in Phase I/II AFFINITY DUCHENNE Trial of RGX-202 in Patients with Duchenne Muscular Dystrophy Ages 1 to 11 Years Old Aug 01
REGENXBIO Inc. Announces Expansion of Affinity Duchenne Trial to Include a New Cohort of Younger Patients Jun 24
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II Jun 18 REGENXBIO Inc. Announces Chief Executive Officer Changes
First quarter 2024 earnings released: US$1.39 loss per share (vs US$1.54 loss in 1Q 2023) May 09
REGENXBIO Inc., Annual General Meeting, May 31, 2024 Apr 05
REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD Mar 28 REGENXBIO Inc. has filed a Follow-on Equity Offering in the amount of $125 million. REGENXBIO Inc. has completed a Follow-on Equity Offering in the amount of $140.000848 million.
REGENXBIO Inc. Announces New Interim Safety and Efficacy Data from Duchenne Trial Mar 05
New minor risk - Shareholder dilution Feb 29
Full year 2023 earnings released: US$6.03 loss per share (vs US$6.50 loss in FY 2022) Feb 28
New major risk - Financial position Feb 08
REGENXBIO Inc. Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint Feb 08
REGENXBIO Inc. Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery Jan 17
New major risk - Financial position Dec 17
REGENXBIO Inc. Announces Dose Escalation in AFFINITY Duchenne®? Trial Nov 30
Third quarter 2023 earnings released: US$1.41 loss per share (vs US$1.75 loss in 3Q 2022) Nov 10
REGENXBIO Inc. Presents Positive One Year Data from Phase II ALTUDE®? Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery Nov 04
New minor risk - Share price stability Nov 01
Vitreous Retina Macula Consultants of New York Announces Participation in Wet AMD Study in Collaboration with Regenxbio Oct 18
REGENXBIO Inc. Announces Additional Interim Safety Data and Initial Efficacy Data from the Phase I/II AFFINITY Duchenne Trial of RGX-202 Oct 05
REGENXBIO Inc. Announces Initial Clinical Data from First Pediatric CLN2 Patient Dosed with RGX-181 Aug 31
Second quarter 2023 earnings released: US$1.66 loss per share (vs US$1.58 loss in 2Q 2022) Aug 03
REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023 Jul 12
First quarter 2023 earnings released: US$1.54 loss per share (vs US$1.79 loss in 1Q 2022) May 05
Full year 2022 earnings released: US$6.50 loss per share (vs US$3.01 profit in FY 2021) Mar 01
REGENXBIO Inc. Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process Feb 12
REGENXBIO Inc. Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, Is Active and Recruiting Patients Jan 24
REGENXBIO Inc. Announces Executive Promotions Jan 10
REGENXBIO Inc. Reports Update on Advancement of Programs for CLN2 Disease Dec 22
Regenxbio Announces Completion of Dosing in the Phase I/Ii Trial of Rgx-111 for the Treatment of Severe Mps I Dec 09
Investor sentiment deteriorated over the past week Nov 10
Third quarter 2022 earnings released: US$1.75 loss per share (vs US$1.37 loss in 3Q 2021) Nov 04
REGENXBIO Inc. Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE(R) Trial of Rgx-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery Nov 04
Investor sentiment improved over the past week Oct 04
Regenxbio Inc. Announces Additional Positive Interim Data from the Phase I/Ii/Iii Campsiite™ Trial of Rgx-121 for the Treatment of Patients Up to 5 Years Old Diagnosed with Mucopolysaccharidosis Type Ii (Mps Ii), Also Known as Hunter Syndrome Sep 01
Investor sentiment deteriorated over the past week Aug 15
Second quarter 2022 earnings released: US$1.58 loss per share (vs US$1.36 loss in 2Q 2021) Aug 04
REGENXBIO Announces Intention to File a Biologics License Application Using the Accelerated Approval Pathway for RGX-121, an AAV Therapeutic for the Treatment of MPS II Aug 04
Executive VP & Chief Financial Officer recently sold €144k worth of stock Jul 16
Investor sentiment improved over the past week Jul 09
REGENXBIO Inc. Announces Enrollment Complete in Cohort 5 of Phase II AAVIATE® Trial Jul 09
Investor sentiment improved over the past week Jun 24
Regenxbio Inc. Appoints Jennifer Zachary to its Board of Directors Jun 08
Investor sentiment deteriorated over the past week May 11
First quarter 2022 earnings released: US$1.79 loss per share (vs US$1.20 loss in 1Q 2021) May 06
REGENXBIO Inc., Annual General Meeting, Jun 03, 2022 Apr 08
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 03
REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery Feb 13
REGENXBIO Inc. Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium™ 2022 Feb 10
REGENXBIO Inc. Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using Subretinal Delivery Jan 12
REGENXBIO Inc. Announces FDA Clearance of IND for Clinical Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy Jan 07
REGENXBIO Inc. Announces Orphan Drug Designation Granted to RGX-202, A Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy Nov 24
Third quarter 2021 earnings released: US$1.37 loss per share (vs US$0.23 profit in 3Q 2020) Nov 03
REGENXBIO Inc. Announces RGX-314 Data Presentations at Retina Society 54th Annual Scientific Meeting Sep 29
Chairman of the Board recently sold €1.9m worth of stock Sep 23
Independent Director Luke Beshar has left the company Sep 10
Second quarter 2021 earnings released: US$1.36 loss per share (vs US$0.91 loss in 2Q 2020) Aug 10
REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy's 24th Annual Meeting May 16
First quarter 2021 earnings released: US$1.20 loss per share (vs US$1.08 loss in 1Q 2020) May 07
Full year 2020 earnings released: US$2.98 loss per share (vs US$2.58 loss in FY 2019) Mar 02 Shareholder Returns RB0 DE Biotechs DE Market 7D 1.3% 1.0% 1.9% 1Y -34.5% -4.3% 15.1%
See full shareholder returns
Return vs Market: RB0 underperformed the German Market which returned 15.1% over the past year.
Price Volatility Is RB0's price volatile compared to industry and market? RB0 volatility RB0 Average Weekly Movement 11.7% Biotechs Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: RB0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RB0's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Show more REGENXBIO Inc. Fundamentals Summary How do REGENXBIO's earnings and revenue compare to its market cap? RB0 fundamental statistics Market cap €385.71m Earnings (TTM ) -€230.38m Revenue (TTM ) €81.35m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) RB0 income statement (TTM ) Revenue US$84.33m Cost of Revenue US$249.31m Gross Profit -US$164.98m Other Expenses US$73.82m Earnings -US$238.80m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -4.82 Gross Margin -195.65% Net Profit Margin -283.19% Debt/Equity Ratio 20.5%
How did RB0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/02 12:24 End of Day Share Price 2025/01/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources REGENXBIO Inc. is covered by 20 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Skorney Baird Huidong Wang Barclays Alec Stranahan BofA Global Research
Show 17 more analysts 
